Quarterly report pursuant to Section 13 or 15(d)

Inventories, net

v3.22.4
Inventories, net
6 Months Ended
Nov. 30, 2022
Inventories, net  
Inventories, net

Note 3. Inventories, net

Inventories were as follows (in thousands):

November 30, 2022

May 31, 2022

Raw materials

$

$

16,264

Work-in-progress

 

 

1,665

Total inventories, net

$

$

17,929

The table below summarizes pre-launch inventories that had been capitalized and charged-off for GAAP accounting purposes due to no longer qualifying for inventory capitalization as pre-launch inventories due to the withdrawal of the BLA submission and estimated expiration based on remaining shelf life. Work-in-progress and finished drug product inventories continue to be physically maintained, can be used for clinical trials, and can be commercially sold upon regulatory approval if the shelf-lives can be extended as a result of the performance of on-going stability tests. Raw material continues to be maintained so that they can be used in the future if needed.

Raw Materials

Work-in-progress

(in thousands, Expiration period ending November 30,)

    

Remaining shelf-life (mos)

    

Specialized

Resins

Other

Total Raw Materials

Bulk drug product

Finished drug product

Total inventories

2023

0 to 12

$

4,764

$

16,264

$

-

$

21,028

$

-

$

-

$

21,028

2024

13 to 24

2,511

-

1,590

4,101

1,661

29,142

34,904

2025

25 to 36

189

-

-

189

-

32,343

32,532

2026

37 to 48

2,115

-

-

2,115

-

-

2,115

Thereafter

49 or more

-

-

-

-

-

-

-

Inventories, gross

9,579

16,264

1,590

27,433

1,661

61,485

90,579

Inventory charge

(9,579)

(16,264)

(1,590)

(27,433)

(1,661)

(61,485)

(90,579)

Inventories, net

$

-

$

-

$

-

$

-

$

-

$

-

$

-

During the first quarter of fiscal year 2023, the Company reviewed purchase commitments made by its manufacturing partner, Samsung BioLogics Co., Ltd. (“Samsung”), under the master agreement between the Company and Samsung, and its vendors for specialized raw materials for which the Company made a prepayment in the amount of

$2.7 million in the third quarter of fiscal year 2022, which were recorded as prepaid expenses in the consolidated financial statements as of May 31, 2022. As discussed in Note 9, Commitments and Contingencies – Commitments with Samsung BioLogics Co., Ltd. (“Samsung”), the Company and its manufacturing partner remain in ongoing discussions about, among other things, deferring the unfulfilled commitments. These additional specialized raw materials are estimated to have shelf-lives ranging from 2023 to 2026. The entire amount was charged-off as of August 31, 2022.

In October 2022, the Company voluntarily withdrew its rolling BLA submission after concluding that a significant risk existed that the BLA would not receive FDA approval due to the inadequate process and performance by its former CRO around the monitoring and oversight of the clinical data from its trials. Following this decision, none of the Company’s inventories now qualify for capitalization as pre-launch inventories. For the three months ended November 30, 2022, the Company charged-off the remaining raw material resin and work-in-progress bulk product inventories of approximately $16.3 million and $1.7 million, respectively.

For additional information, refer to Note 2, Summary of Significant Accounting Policies – Pre-launch Inventories in this Form 10-Q, and to Note 3, Inventories, net, in the 2022 Form 10-K.